Field Trial



Dry-mist of hydrogen peroxide compares favorably with manual cleaning with ammonia for decontamination of hospital rooms

Introduction: The efficacy of dry-mist hydrogen peroxide decontamination has been determined in various healthcare settings in several countries, including operating rooms, intensive care units, infectious disease units, laboratories, and ambulances. (See Figure 1) The dry-mist disinfectant diffuses over a wide area, reaching even inaccessible areas that may be missed by manual wiping. To further study* the technique, investigators in France conducted a comparison of dry-mist hydrogen peroxide with directed spray decontamination. Efficacy of the technique against *Aspergillus spp* contamination in a laboratory also was studied. Results indicated that dry-mist hydrogen peroxide can be used both preventively and as a treatment during nosocomial bacterial outbreaks.



Study project: Six to eight contamination-prone areas in hospital rooms recently vacated by patients were sampled using Count-Tact agar plates (BioMeriéux). Sets of samples were collected in the department of infectious diseases and the reanimation unit. After sampling, the rooms were cleaned and then decontaminated with either a dry-mist of hydrogen peroxide (Gloster Sante Europe) or manual spraying with quaternary ammonium, selected randomly. After decontamination, surfaces were resampled. In all, 80 sets of samples were collected, for a total of 560 samples.

Findings: Before cleaning and decontamination, bacteria were recovered at average densities ranging up to 690 cfu/100cm2. The following pathogenic bacteria were identified in the samples: *Enterobacter aerogenes, Klebsiella pneumoniae, Staphylococcus aureus*, multidrug-resistant *Staphylococcus aureus* (MRSA; only in the infectious diseases department), *Clostridium perfringens*, and *Acinetobacter baumanii* (only in the infectious diseases department). After decontamination with a dry-mist of hydrogen peroxide

"A comparison between manual surface disinfection using directed spray and [dry-mist hydrogen peroxide decontamination has shown that the latter is more effective in actual healthcare situations in high-risk medical facilities."

(standard cycle), bacteria were recovered at mean densities of 0 to 7 cfu/ 100cm², and no pathogens were recovered. This decrease in recovered pathogens was statistically significantly better than the decrease seen when cleaning was followed by decontamination by manual spraying with quaternary ammonium (200-fold compared with 150-fold, P<0.0001).

Study project: Three laboratories were suspected of becoming contaminated with mold while undergoing upgrade of a fire prevention system. Eight to 12 samples were taken from each laboratory before it was cleaned. After cleaning followed by decontamination with a dry-mist of hydrogen peroxide (standard cycle), sampling was repeated.

Findings: Aspergillus was recovered from all three laboratories before they were cleaned. After cleaning and decontamination, no Aspergillus or other mold was recovered, even from surfaces that were difficult to reach, such as racks inside incubators. (See Figure 2) The difference in presence of Aspergillus spp before and after cleaning/disinfection was statistically significant (P<0.05).



Conclusion: The authors concluded that the dry-mist hydrogen peroxide decontamination system should provide facilities with an effective method for controlling the spread of infectious diseases, noting that the method can be used both preventatively during routine decontamination and as a treatment during infectious disease outbreaks.

Source*: Marty N, Cavalié L, Conil J, Roques C. Dry fog disinfection: an assessment of microbiological efficacy and practical advantages. *Revue Hygienes* 2007;15:317-20.

ADVANCED STERILIZATION PRODUCTS

Division of Medos International Sàrl

a Johnson Johnson company

While every care has been taken in the compilation of these summaries and every attempt made to present up-to-date and accurate information, we cannot guarantee that inaccuracies will not occur. ASP will not be held responsible for any claim, loss, damage or inconvenience caused as a result of any information on this page. Recipients of this literature brochure are encouraged to review the entire articles on their own and form their own conclusions.

FOR MORE

Contact for UK

ASP c/o J&J Medical Ltd. Pinewood Campus, Nine Mile Ride Wokingham Berkshire RG40 3EW, England T : +44 1 344 871 081 F : +44 1 344 871 171

Contact for Ireland

ASP c/o J&J Medical Ireland Airton Rd, Tallaght Dublin 24, Ireland T : +353 1 466 5200 F : +353 1 466 5340

Contact for Egypt

Johnson & Johnson Medical Egypt Florida Mall 5th Floor 1229 Square El Sheikh Ali Gad El Hak St. Heliopolis Cairo, Egypt T : +202 2268 5026 F : +202 2268 4674

Contact for Middle East

ASP c/o J&J Medical Middle East Dubai Healthcare City, J&J building, 3rd floor PO Box 505080, Dubai, United Arab Emirates T : +97 1 4 429 7235 F : +97 1 4 429 7250

Contact for South Africa

ASP c/o J&J Medical Pty Ltd SA PO Box 273, Midrand Halfway House 1685 Republic of South Africa T : +271 1 265 1120 F : +27 11 265 1189